The distribution of the magnetic resonance imaging response to glatiramer acetate in multiple sclerosis
- 1 August 2005
- journal article
- research article
- Published by SAGE Publications in Multiple Sclerosis Journal
- Vol. 11 (4) , 447-449
- https://doi.org/10.1191/1352458505ms1178oa
Abstract
We investigated the distribution of the magnetic resonance imaging (MRI)-measured response to glatiramer acetate (GA) treatment in multiple sclerosis (MS) using data from a clinical trial of relapsing=remitting (RR) MS. A fixed and a random effects model were used to quantify the between-patient heterogeneity in treatment response, expressed as new enhancing lesion percentage reduction. In 95% of the patients, lesion reduction due to treatment was estimated to range between -20% and -54%, indicating a rather homogeneous effect of GA on MRI-measured disease activity in RRMS.Keywords
This publication has 8 references indexed in Scilit:
- Effect of glatiramer acetate on MS lesions enhancing at different gadolinium dosesNeurology, 2002
- MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patientsNeurology, 2002
- European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosisAnnals of Neurology, 2001
- Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon-?1a in relapsing-remitting multiple sclerosisAnnals of Neurology, 1999
- Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trialsJournal of the Neurological Sciences, 1999
- Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosisAnnals of Neurology, 1998
- Characterization of MRI response to treatment with interferon beta-1b: Contrast-enhancing MRI lesion frequency as a primary outcome measureNeurology, 1997
- Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosisNeurology, 1993